Trials / Terminated
TerminatedNCT04059198
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic Treatment-Naive Subjects Infected With Chronic Hepatitis B Virus
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- F-star Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inarigivir soproxil | Inarigivir soproxil 400 mg tablets |
| DRUG | Tenofovir alafenamide fumarate (TAF) | Tenofovir alafenamide fumarate 25 mg tablet |
Timeline
- Start date
- 2019-10-10
- Primary completion
- 2020-04-02
- Completion
- 2020-04-02
- First posted
- 2019-08-16
- Last updated
- 2020-07-21
Locations
2 sites across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT04059198. Inclusion in this directory is not an endorsement.